European Psychiatry - Volume 41 - April 2017

541 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S521–S582 S537
in order to collect and analyse information on the state of health
and health-related behaviors of the citizens of Nicosia in Cyprus.
Aims To estimate the frequency of self-reported depressive dis-
orders and examine burdening as well as factors influencing it.
Methods Based on the 2011 census, a cross-sectional study was
carried out on a representative random stratified sample, which
was selected to be interviewed, including 477men and 525women,
from the city area. Participants answered a questionnaire, which
required among other items on self-perceived physical and mental
health. Participants were also asked the following questions: “Do
you have/had in the past depression or/and anxiety?” and “Have
you received a medical diagnosis for this disorder?”
Results Approximately 70% of the sample reported they had
experienced anxiety and depression (37% moderate and 33%
severe episodes). Diagnosed depression was reported by 4%.
Severe depressive disorders were more frequently reported by
women (41%, P < 0.001), older aged citizens (70.2%, P < 0.001)
widowed/divorced (45.5%, P < 0.001), persons with lower family
income (< 1000 D , 79.7%, P < 0.001) and among people with chronic
diseases (45.3%, P < 0.001).
Conclusions The self-reported prevalence of anxiety and depres-
sion in the citizens of Nicosia is very high – probably reflecting
a negative effect of the economic crisis –, and contrariwise diag-
nosis of the disorder is rarely provided and consequently therapy
rarely offered. Specific population groups, such as women, elderly
citizens, patients with chronic diseases are more vulnerable to
depressive disorders requiring specialized medical attention.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0408
The onset, course and resolution of
depressive symptomatology in
chronic hepatitis C patients on
pegylated interferon alpha: A 72-week
prospective study
Z. Pavlovic ∗ Jasovic-Gasic Delic Maric
O. Vukovic , S. Pejovic , M. Mihaljevic , S. Andric , M. Jovicic
1 Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine-
University of Belgrade, Belgrade, Serbia
2 University of Belgrade, School of Medicine, Belgrade, Serbia
3 3Institute of Infectious and Tropical Diseases,Prof. Dr. Kosta
Todorovi´c, Clinical Center of Serbia, Belgrade- Serbia, School of
Medicine, University of Belgrade, Belgrade, Serbia
4 Institut of Mental Health Belgrade, Serbia, School of Medicine,
University of Belgrade, Belgrade, Serbia
5 Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine,
Univeristy of Belgrade, Belgrade, Serbia
6 Clinic for Psychiatry Clinical Centre of Serbia, School of Medicine,
University of Belgrade, Belgrade, Serbia
7 Clinical Centre of Serbia, Clinic for Psychiatry, Belgrade, Serbia
∗ Corresponding author.
Introduction Treatment with pegylated interferon alpha (PEG-
IFN- ) in patients with chronic hepatitis C (CHC) is associated with
depressive symptomatologymore frequently than other inflamma-
tory diseases treated with PEG-IFN- .
Objectives To prospectively evaluate the onset, course and reso-
lution of depressive symptomatology in CHC patients treated with
PEG-IFN- .
Methods Hamilton depression rating scale (HAMD) was used
to asses depressive symptoms in 103 subjects with CHC prior to
initiation of PEG-IFN- (mean dose 152.6 ±25.6mcg; duration of
therapy 48 weeks) and at the follow-up visits (4th, 12th, 24th, 48th
and 72thweek). Control group consisted of 103 CHC subjects, with-
out PEG-IFN- .
Results Our results showed a significant increase in HAMD scores
as early as in the 4th week of PEG-IFN-a therapy compared to
HAMD scores prior to initiation of PEG-IFN- (38.8% vs. 24.3%).
The peak of depressive symptomatology was evidenced in the 12th
week (mean HAMD 9.34± 6.93), when almost 50% of patients had
HAMD above 7. At the end of the treatment (48th week), 38.8% had
HAMD above 7, and in the 72nd week (24 weeks after the therapy
completion) prevalence of depression was decreased to the values
lower than at baseline (23.3% vs. 24.3%). No change in prevalence
of depression was detected in control group.
Conclusion Our results are important because they show the
overall course of depressive symptomatology during the interferon
therapy. These data also show spontaneously resolution of depres-
sion 6 months after the completion of PEG-IFN- . This study is the
longest study in this area.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0409
Presence of somatic symptoms
(especially pain) in patients with
depresive disorder and its impact on
quality of life, and possible
involvement with anhedonia
A.L. Pérez Morenilla ∗, A. Salazar , I. Failde , J.A. Mico
1 University Hospital Puerta del Mar, Cádiz, Psychiatry, Cádiz, Spain
2 INIBICA Instituto de Investigación e Innovación en Ciencias
Biomédicas, Neurosciences, Cádiz, Spain
3 University of Cádiz, Preventive Medicine and Public Health, Cádiz,
Spain
4 University of Cádiz, Neuroscience Pharmacology and Psychiatry,
Cádiz, Spain
5 CIBER of Mental Health CIBERSAM, Group 18, Cádiz, Spain
∗ Corresponding author.
Depressive Disorder, according to WHO will be one of the most
disabling causes in the world. Depression includes psycholog-
ical and somatic symptoms, like anhedonia or pain, and both
have a bidirectional relationship, so that the presence and sever-
ity of one of them directly affects the other one, and both leads
to a disruption in quality of life and increase health resources.
The relationship between major depression and chronic pain
has been widely investigated but few studies have focused on
other depressive spectrum disorders, and never the possible rela-
tionship between pain and anhedonia in DD. Our aim is to
analyse the presence of somatic symptoms (especially pain) in
patients with DD and its impact on quality of life, and involve-
ment with anhedonia. We analysed the correlation between the
scores of the HADS, SSI-28, SHAPS and SF-36 scales. Results
showed a significant correlation between SSI-28 and HADS-
A(r = 0.45; P < 0.001), HADS-D(r = 0.35; P < 0.001) and with 7 of
the 8 domains of SF-36: Bodily Pain(r= –0.62; P < 0.001), Gen-
eral Health( r= –0.29; P = 0.003), Role Physical(r = –0.45; P < 0.001)
Mental Health(r = –0.34; P = 0.003), Vitality(r = –0.403; P< 0.001),
Social Functioning(r= –0.37; P < 0.001). In addition, SHAPS corre-
lates with 6 of the 8 domains of SF-36: PF(r = –0.33; P= 0.001),
GH(r= –0.27; P = 0.006), Vit (r = –0.41; P < 0.001), SF(r= –0.52;
P < 0.001), RE(r= –0.24; P < 0.001) and MH(r= –0.49; P < 0.001). The
results demonstrate that both anhedonia and somatic symptoms
negatively correlate with HRQoL, and that a bidirectional relation-
ship between depression and somatic symptoms is clearly proven,
which means that depression may be related with the presence
of somatic symptoms, especially pain, and also somatic symptoms
lead to an increase of depressive symptoms. This could impact on
the diagnosis and treatment of depressed patients with somatic
symptoms and anhedonia.